← Back

KPC Pharmaceuticals Inc

KPC Pharmaceuticals, Inc. is a pharmaceutical company engaged in the research, development, production, marketing, and commercial wholesale of botanical and natural drugs in China and internationally. Its products include artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescriptions for bones and joints, antibiotics, immunosuppressants, oral products, and injections. The company also wholesales and retails medicines and equipment, covering therapeutic areas such as cardiovascular and cerebrovascular, orthopedics, antimalarial, gynecology, and digestive system. It markets products under brands including Luotai, Tianxuanqing, Artemedine, Artem, and Arco. Formerly Kunming Pharmaceutical Corporation, it changed its name to KPC Pharmaceuticals, Inc. in April 2015. Founded in 1951, the company is based in Kunming, China.

Country
Price · split & dividend adjusted
News & notes moving 600422.CG
China
600422.CG▲

KPC Pharmaceuticals' 1 Billion Yuan Medium-Term Note Registration Application Approved

KPC Pharmaceuticals announced that its 1 billion yuan medium-term note registration application has been accepted by the National Association of Financial Market Institutional Investors. The registration quota is valid for two years from the date of the notice, with Industrial Bank, China Merchants Bank, and Bank of China serving as joint lead underwriters. The company may issue the notes in tranches during the registration validity period, and after each issuance is completed, it must disclose the issuance results through channels recognized by the association.
600422.CG · Capital · Positive KPC Pharmaceuticals' 1 billion yuan medium-term note registration application was accepted, giving it a new debt-financing channel.
Read original ↗
Jiemian·34dRead more →
China
600422.CG▼3

Kunming Pharmaceutical Group reports net loss of 364 million yuan in 2026 interim report

Kunming Pharmaceutical Group released its 2026 interim report, with net profit attributable to the parent company at negative 364 million yuan, swinging from profit to loss year on year. Total operating revenue was 1.643 billion yuan, down 50.97 percent from the same period last year. Net cash flow from operating activities was negative 514 million yuan, a year-on-year decline of 334.90 percent. The latest gross margin was 19.27 percent, down 20.58 percentage points from the same period last year. Diluted earnings per share were negative 0.48 yuan. The company's latest asset-liability ratio was 41.37 percent, and the number of shareholders was 52,200.
600422.CG · Capital · Negative Net loss of 364 million yuan, revenue down 50.97%, and negative operating cash flow.
Read original ↗
Jiemian·44dRead more →
600422.CG▲

15 Stocks Register for Dividends Today, Dazzle Fashion Leads with 4 Yuan per 10 Shares

Based on the equity registration date, a total of 15 listed companies will implement their 2025 dividend plans today. Among them, 10 companies have a cash dividend of 1 yuan or more per 10 shares. Dazzle Fashion is the most generous, distributing 4.00 yuan per 10 shares, followed by COSCO Shipping Specialized Carriers and Huaxia Bank, with cash dividends of 3.25 yuan and 3.20 yuan per 10 shares respectively. In terms of share transfers, Chengzhi Shareholding has the highest ratio, with a transfer of 4 shares for every 10 shares held. Regarding recent stock performance, KPC Pharmaceuticals has led these 15 stocks with a cumulative gain of 3.76% over the past five trading days.
000990.CS · Capital · Positive Chengzhi Shareholding has the highest share transfer ratio (4 for 10) among the 15 stocks registering dividends today.
603587.CG · Capital · Positive Dazzle Fashion leads with the highest cash dividend of 4.00 yuan per 10 shares, a strong capital return to shareholders.
600015.CG · Capital · Positive Hua Xia Bank is distributing a cash dividend of 3.20 yuan per 10 shares, a positive capital return to shareholders.
600428.CG · Capital · Positive COSCO Shipping Specialized Carriers is distributing a cash dividend of 3.25 yuan per 10 shares, a positive capital return.
600422.CG · Capital · Positive KPC Pharmaceuticals has led the 15 stocks with a 3.76% gain over the past five trading days, indicating positive market reception.
Read original ↗
证券时报·68dRead more →
600422.CG▼

KPC Pharmaceuticals Plans to Sell Up to 2.44 Million Shares in Vinet Biotech, Expected Transaction Value of 132 Million Yuan

KPC Pharmaceuticals announced plans to sell up to 2.44 million shares in Vinet Biotech through methods such as centralized bidding and block trades, with an expected transaction value of 132 million yuan and a book cost of 113 million yuan. In the first quarter of 2026, KPC Pharmaceuticals achieved revenue of 836 million yuan, with a net loss attributable to the parent company of 142 million yuan.
600422.CG · Capital · Negative KPC Pharmaceuticals plans to sell shares in Vinet Biotech at a loss (book cost 113M vs expected transaction value 132M, but net loss of 142M in Q1 2026 indicates financial strain).
Read original ↗
财中社·73dRead more →
600422.CG▼2

KPC Pharmaceuticals Plans to Sell Up to 2,443,022 Shares of Leed Biotech

KPC Pharmaceuticals announced that, in order to further strengthen its core business and optimize its asset structure, the company plans to sell up to 2,443,022 shares of Nanjing Leed Biotech Co., Ltd. through methods such as centralized bidding and block trades at an opportune time.
600422.CG · Capital · Negative KPC Pharmaceuticals plans to sell shares of Leed Biotech, which may signal a need to raise cash or divest assets, potentially reducing its investment value.
Read original ↗
证券时报·73dRead more →